Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum.
Cells, Cultured
Corneal Diseases
/ drug therapy
Corneal Keratocytes
/ drug effects
Gene Expression Profiling
Gene Expression Regulation
/ drug effects
Humans
Indicator Dilution Techniques
Intercellular Signaling Peptides and Proteins
/ analysis
Ophthalmic Solutions
/ pharmacology
Platelet-Rich Plasma
/ chemistry
Proteome
/ analysis
Serum
/ chemistry
AS
PRGF
PRP
autologous serum
cornea
keratocytes
ocular surface
plasma rich in growth factors
platelet-rich plasma
proteomic
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Nov 2021
10 Nov 2021
Historique:
received:
23
09
2021
revised:
03
11
2021
accepted:
09
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
20
1
2022
Statut:
epublish
Résumé
Over the last three decades, there has been special interest in developing drugs that mimic the characteristics of natural tears for use it in the treatment of several ocular surface disorders. Interestingly, the composition of blood plasma is very similar to tears. Therefore, different blood-derived products like autologous serum (AS) and plasma rich in growth factors (PRGF) have been developed for the treatment of diverse ocular pathologies. However, scarce studies have been carried out to analyze the differences between both types of blood-derived products. In the present study, blood from three healthy donors was drawn and processed to obtain AS and PRGF eye drops. Then, human corneal stromal keratocytes (HK) were treated with PRGF or undiluted AS. Proteomic analysis was carried out to analyze and characterize the differential protein profiles between PRGF and AS, and the differentially expressed proteins in HK cells after PRGF and AS treatment. The results obtained in the present study show that undiluted AS induces the activation of different pathways related to an inflammatory, angiogenic, oxidative stress and scarring response in HK cells regarding PRGF. These results suggest that PRGF could be a better alternative than AS for the treatment of ocular surface disorders.
Identifiants
pubmed: 34830053
pii: ijms222212176
doi: 10.3390/ijms222212176
pmc: PMC8618701
pii:
doi:
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Ophthalmic Solutions
0
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Basque Government
ID : KK-2019/00094
Références
Invest Ophthalmol Vis Sci. 1995 Sep;36(10):2120-6
pubmed: 7544783
Cutan Ocul Toxicol. 2011 Mar;30(1):7-14
pubmed: 21091383
Oxid Med Cell Longev. 2015;2015:591530
pubmed: 25861412
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
Exp Eye Res. 2013 Oct;115:153-61
pubmed: 23872360
Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1185-94
pubmed: 21494875
PLoS One. 2018 Oct 12;13(10):e0205073
pubmed: 30312303
Exp Eye Res. 2016 Oct;151:115-21
pubmed: 27567559
Cornea. 1996 Sep;15(5):505-16
pubmed: 8862928
Arch Soc Esp Oftalmol. 2016 Oct;91(10):475-90
pubmed: 27062018
Cochrane Database Syst Rev. 2017 Feb 28;2:CD009327
pubmed: 28245347
Acta Ophthalmol. 2015 Nov;93(7):654-7
pubmed: 26178796
Mol Cell Proteomics. 2002 Nov;1(11):845-67
pubmed: 12488461
Invest Ophthalmol Vis Sci. 2020 Sep 1;61(11):19
pubmed: 32926102
Int J Oral Maxillofac Implants. 1999 Jul-Aug;14(4):529-35
pubmed: 10453668
Curr Pharm Biotechnol. 2012 Jun;13(7):1185-95
pubmed: 21740373
Invest Ophthalmol Vis Sci. 2013 Jul 02;54(7):4452-8
pubmed: 23716625
Ocul Immunol Inflamm. 2004 Jun;12(2):87-99
pubmed: 15512979
Farm Hosp. 2011 Jan-Feb;35(1):8-13
pubmed: 20619713
Prog Retin Eye Res. 2000 Jan;19(1):113-29
pubmed: 10614683
Taiwan J Ophthalmol. 2017 Oct-Dec;7(4):213-220
pubmed: 29296554
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Regen Med. 2017 Jul;12(5):565-574
pubmed: 28758836
Cochrane Database Syst Rev. 2013 Aug 27;(8):CD009327
pubmed: 23982997
Clin Exp Ophthalmol. 2020 Aug;48(6):830-838
pubmed: 32342597
Arthroscopy. 2012 Jul;28(7):998-1009
pubmed: 22738751
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3662-70
pubmed: 19324862
Exp Eye Res. 2006 May;82(5):788-97
pubmed: 16303127
Invest Ophthalmol Vis Sci. 1990 Sep;31(9):1773-8
pubmed: 2211024
Int Ophthalmol. 2018 Jun;38(3):1193-1204
pubmed: 28620707
Growth Factors. 2013 Aug;31(4):115-22
pubmed: 23777359
Transfus Apher Sci. 2017 Aug;56(4):595-604
pubmed: 28844373
Ophthalmic Res. 2016 Jul;56(2):68-73
pubmed: 27229893
Annu Rev Biochem. 1999;68:459-86
pubmed: 10872457
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Br J Ophthalmol. 2004 Nov;88(11):1467-74
pubmed: 15489495
Exp Eye Res. 2015 Jun;135:118-26
pubmed: 25708868
Sci Rep. 2016 Dec 02;6:38143
pubmed: 27909310
J Histochem Cytochem. 2002 Mar;50(3):341-51
pubmed: 11850437
Mol Cell Proteomics. 2004 Apr;3(4):311-26
pubmed: 14718574
Invest Ophthalmol Vis Sci. 2013 Nov 13;54(12):7424-30
pubmed: 24106124
Invest Ophthalmol Vis Sci. 2012 Aug 15;53(9):5571-8
pubmed: 22786903
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2936-45
pubmed: 18579759
Graefes Arch Clin Exp Ophthalmol. 1995 Nov;233(11):694-8
pubmed: 8566825
Am J Med Sci. 2011 Jul;342(1):62-9
pubmed: 21139494
Ophthalmology. 2009 Sep;116(9):1624-9
pubmed: 19729097
Invest Ophthalmol Vis Sci. 2000 May;41(6):1346-55
pubmed: 10798649
Acta Ophthalmol Scand. 2004 Oct;82(5):557-63
pubmed: 15453853
BMJ Open Sport Exerc Med. 2016 Feb 4;2(1):e000060
pubmed: 27900152
PM R. 2015 Apr;7(4 Suppl):S53-S59
pubmed: 25864661
Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2490-5
pubmed: 11581188
Ann Anat. 2013 Oct;195(5):461-6
pubmed: 23722041
Br J Ophthalmol. 2004 May;88(5):647-52
pubmed: 15090417
Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2062-75
pubmed: 22395876
Ophthalmic Res. 1995;27(3):136-43
pubmed: 8538990
Am J Ophthalmol. 2006 Nov;142(5):757-64
pubmed: 16989763
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Invest Ophthalmol Vis Sci. 2011 Aug 01;52(9):6066-73
pubmed: 21613374
J Thromb Haemost. 2018 Sep;16(9):1895-1900
pubmed: 30099839
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Am J Manag Care. 2008 Apr;14(3 Suppl):S88-101
pubmed: 18452372
Eur J Ophthalmol. 2020 Jan;30(1):94-103
pubmed: 30585084
Expert Opin Biol Ther. 2020 Dec;20(12):1447-1460
pubmed: 32692595
Invest Ophthalmol Vis Sci. 2012 Nov 15;53(12):7645-53
pubmed: 23074205
Invest Ophthalmol Vis Sci. 1996 Mar;37(4):630-6
pubmed: 8595963
Curr Med Chem. 2011;18(6):931-42
pubmed: 21182473
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Ophthalmol Eye Dis. 2014 Jun 24;6:37-42
pubmed: 25002818
Int J Mol Sci. 2020 Feb 04;21(3):
pubmed: 32033116
Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2
pubmed: 10889110
Cornea. 2014 Jun;33(6):614-20
pubmed: 24727633
Cornea. 2009 Dec;28(10):1104-8
pubmed: 19730088
Acta Ophthalmol. 2015 Dec;93(8):e605-14
pubmed: 25832910